Skip to main content
Have a personal or library account? Click to login
BioFire® FilmArray® Pneumonia Panel versus bacterial culture in adult community acquired pneumonia: treatment implications Cover

BioFire® FilmArray® Pneumonia Panel versus bacterial culture in adult community acquired pneumonia: treatment implications

Pneumologia
Volume 74 (2025): Issue 1 (January 2025)
By: ,  ,  ,   and    
Open Access
|Oct 2025
Figures & tables

Figures & Tables

Table 1.

Targets of the BioFire pneumonia panel

BacteriaAtypical bacteriaVirusesAntimicrobial resistance genes
Strept_agalactiaeChlamydia_PAdenovirusIMP
Strept PneumoniaeLegionella_PCoronavirusKPC
Strept_PyogenesMycoplasma_PHuman_MetapneumovirusmecA_C_and_MREJ
Moraxella_catarrhalisHuman_Rhinovirus_EnterovirusNDM
ProteusINFLUENZA_BOXA_48_like
Pseudomonas aeruginosaINFLUENZA_AVIM
Serratia_marcescensMERS_CoVIMP
Staph_aureusParainfluenzaKPC
E._ColiRSVIMP
H_influenzae
Klebsiella_aerogenes
Klebsiella_oxytoca
Klebsiella_Pneumoniae
Acinetobacter calcoaceticus baumannii_complec
Enterobacter cloacae complex

1 IMP, Imipenemase metallo-β-lactamase; KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-β-lactamase; VIM, Verona integron-encoded metallo-β-lactamase.

Table 2.

Characteristic data of participating subjects

MeanSD
Age (years)62.8918.61
Age category (F/%)
18–35 (years)3314.0
36–50 (years)3113.1
51–65 (years)4217.8
>65 (years)13055.1
Sex (F/%)Male15063.6
Female8636.4
Smoking status (F/%)
Current smoker14059.3
Ex-smoker166.8
Non-smoker8033.9
SI (Pack.year)17.9418.36
Comorbidities (F/%)
DM12753.81
HTN11046.6
IHD8536.0
Chr_Resp_Dis3715.68
CKD3615.25
Others5523.3
Antimicrobial use before hospitalisation (F/%)18477.96
Hosp_LOS (days)23.4932.32
ICU_LOS (days)16.9521.91
MV_Dur (days)5.9514.82
Outcome (F/%)Discharged17674.6
In-hospital mortality6025.4
30-day mortality (F/%)4318.22

1 CKD, chronic kidney disease; CRP, C-reactive protein; diff, differential count; DM, diabetes mellitus; F/%, frequency/percentage; HTN, hypertension; ICU, intensive care unit; IHD, ischaemic heart disease; LOS, length of stay; MV, mechanical ventilation; SD, standard deviation; SI, smoking index; TLC, total leucocytic count.

Figure 1.

Overview of BFPP results in comparison to the standard culture method. BFPP, BioFire® FilmArray® pneumonia panel; SOC, standard of care.

Figure 2.

Percentages of detected bacteria by BFPP and SOC. BFPP, BioFire® FilmArray® pneumonia panel; SOC, standard of care.

Table 3.

Qualitative detection of bacterial targets between the BioFire PN Panel and SOC culture

Specimens (no of BFPP detections/no of standard culture detections)
(+/+) True Positive(±) False Positive(-/+) False Negative(-/-) True NegativePPA%. [95% CI]NPA%. [95% CI]OPA%. [95% CI]
Strept_agalactiae0130223NA94.49 [90.76–97.03]94.51 [90.76–97.03]
Strept Pneumoniae17022899.58 [97.64–99.98]97.02 [93.96–98.79]97.03 [93.98–98.80]
Strept_Pyogenes010235NA99.58 [97.66–99.99]99.58 [97.67–99.99]
Moraxella_catarrhalis020234NA99.15 [96.97–99.90]97.05 [94.01–98.80]
Proteus16022999.58 [97.64–99.98]97.41 [94.46–99.05]97.5 [94.48–99.1]
Pseudomonas aeruginosa2128418389.41 [84.83–92.72]86.7 [73.61–83.92]86.44 [81.40–90.54]
Serratia_marcescens070229100 [98.40–100.0]97.03 [93.98–98.80]97.05 [94.01–98.80]
Staph_aureus1022020495.76 [92.38–97.68]90.3 [85.63–93.80]90.68 [86.23–94.07]
E._Coli2221319088 [84.83–92.72]90.05 [85.19–93.73]89.83 [85.25–93.37]
H_influenzae16022999.58 [97.64–99.98]97.45 [94.53–99.06]97.46 [94.55–99.06]
Klebsiella_aerogenes050231100 [98.40–100.0]97.88 [95.13–99.31]97.89 [95.15–99.31]
Klebsiella_oxytoca14023199.58 [97.64–99.98]98.30 [95.70–99.53]98.31 [95.72–99.54]
Klebsiella_pneumoniae36251316273.47 [58.92–85.05]86.63 [80.90–91.16]83.90 [78.58–88.35]
Acinetobacter calcoaceticus baumannii_complec720220796.19 [92.91–97.98]91.2 [83.87–92.02]90.68 [86.23–94.07]
Enterobacter cloacae complex116021999.58 [97.64–99.98]93.19 [89.18–96.06]93.22 [89.22–96.08]
Total bacterial pathogens100177223,00681.97 [73.98–88.34]94.44 [93.59–95.21]93.98 [93.11–94.77]

1 BFPP, BioFire® FilmArray® pneumonia panel; CI, confidence interval; NA, not applicable; NPA, negative percent agreement; OPA, overall percent agreement; PN, Pneumonia; PPA, positive percent agreement; SOC, standard of care.

Figure 3.

Percentages of viruses detected by BFPP. BFPP, BioFire® FilmArray® pneumonia panel.

Table 4.

Frequency and percentage of resistance genes

FrequencyPercent (%)
Carbapenemase producing Gram negative bacilliVIM93.81
IMP20.85
KPC20.85
NDM6025.42
OXA-48 like4217.8
Total carbapenamase producers11548.73
ESBL producing bacteriaCTX_M7531.78
Methicillin resistant Staphylococcus aureusmecA_C_and_MREJ2410.17
Total21490.68

1 ESBL, extended-spectrum beta lactamase.

Table 5.

Comorbid disease association with infecting organisms

DMChronic respiratory diseaseCKDHTNIHDOther diseases
Klebsiella pneumoniae2221.630.610.228.225.5
Pseudomonas aeronginosa18.935.113.911.42029.1
E. coli11.810.830.65.12014.5
Acinetobacter baumannii13.45.416.78.92016.4
Enterobacter_cloacae_complex4.710.811.137.19.1
Staphylococcus aureus11215.65.115.318.2
BF_Strept_agalactiae7.18.18.32.14.75.5
BF_Strept_P3.92.75.61.73.51.8
BF_Strept_Pyogenes000000
BF_Moraxella_catarrhalis0.802.80.82.41.8
BF_Proteus2.45.48.30.85.91.8
BF_Serratia_marcescens3.95.401.74.71.8
BF_H_influenzae4.72.72.82.12.41.8
BF_Klebsiella_aerogenes0.88.111.10.42.43.6
BF_Klebsiella_oxytoca2.45.42.80.43.51.8

1 BF, Bronchial fluid; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; IHD, ischaemic heart disease.

Table 6.

Comorbid disease association with resistance genes

DMHTNIHDChronic respiratory diseaseCKDOthers
VIM2.42.52.48.12.81.8
IMP1.60.41.2001.8
KPC0002.700
mecA_C_and_MREJ7.13.810.610.82.810.9
NDM22.81434.124.333.330.9
OXA_48_like14.26.822.413.522.220
CTX_M27.613.634.12727.834.5

1 CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; IHD, ischaemic heart disease.

DOI: https://doi.org/10.2478/pneum-2025-0027 | Journal eISSN: 2247-059X | Journal ISSN: 2067-2993
Journal RSS Feed
Language: English, Romanian
Page range: 48 - 60
Published on: Oct 31, 2025
Published by: Romanian Society of Pneumology
In partnership with: Paradigm Publishing Services
Publication frequency: Volume open
Keywords:
sCAP,
BioFire,
Pneumonia Panel,
VITEK-2,
antibiotic resistance
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other,
Internal medicine,
Pneumology

© 2025 Samir Mohamed Mahmoud Fahyim, Hesham Atef AbdelHalim, Heba Helmy AboElNaga, Rania Talaat Abdel Haleem, El Shaimaa Sabry Mohammed Hassan, published by Romanian Society of Pneumology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 74 (2025): Issue 1 (January 2025)
Previous article
Next article